ERBB2 and breast carcinoma: A recent review including altogether 15 studies in patients aged 65 or older clinical confirmed the prognostic performance of Oncotype DX® and Prosigna® risk of recurrence in older patients with HR-positive, HER2-negative breast cancer [40].